Jonathan I. Lieber

Insider Reports History

Entity
Individual
Location
C/O Histogenics Corporation, 830 Winter Street #3, Waltham, MA
Signature
/s/Mark Rosenblum, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Jonathan I. Lieber:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Rallybio Corp Chief Financial Officer Option (Right to Buy) 120K $212K $1.77 Feb 15, 2024 Direct
Rallybio Corp Chief Financial Officer Common Stock 5K $41K $8.20 Mar 14, 2023 Direct
Salarius Pharmaceuticals, Inc. Director Stock Option (right to buy) 20.5K Feb 20, 2024 Direct
APPLIED GENETIC TECHNOLOGIES CORP Chief Financial Officer Stock Option (Right to Buy) 0 Nov 30, 2022 Direct

Insider Reports Filed by Jonathan I. Lieber

Symbol Company Period Transactions Value $ Form Type Date Filed Role
SLRX Salarius Pharmaceuticals, Inc. Feb 20, 2024 1 $0 4 Feb 22, 2024 Director
RLYB Rallybio Corp Feb 15, 2024 1 $0 4 Feb 16, 2024 Chief Financial Officer
RLYB Rallybio Corp Mar 14, 2023 1 $26.1K 4 Mar 16, 2023 Chief Financial Officer and Treasurer
RLYB Rallybio Corp Feb 1, 2023 1 $0 4 Feb 1, 2023 Chief Financial Officer and Treasurer
RLYB Rallybio Corp Feb 1, 2023 0 $0 3 Feb 1, 2023 Chief Financial Officer and Treasurer Exhibit List: Exhibit 24 - Power of Attorney
SLRX Salarius Pharmaceuticals, Inc. Jan 3, 2023 1 $0 4 Jan 5, 2023 Director
AGTC APPLIED GENETIC TECHNOLOGIES CORP Nov 30, 2022 2 $0 4 Dec 1, 2022 Chief Financial Officer
AGTC APPLIED GENETIC TECHNOLOGIES CORP Aug 21, 2022 1 $0 4 Aug 24, 2022 Chief Financial Officer
SLRX Salarius Pharmaceuticals, Inc. Jun 7, 2022 1 $7.02K 4 Jun 8, 2022 Director
SLRX Salarius Pharmaceuticals, Inc. Jan 20, 2022 1 $0 4 Jan 21, 2022 Director
AGTC APPLIED GENETIC TECHNOLOGIES CORP Sep 20, 2021 1 $0 4 Sep 21, 2021 Chief Financial Officer
AGTC APPLIED GENETIC TECHNOLOGIES CORP Sep 20, 2021 0 $0 3 Sep 21, 2021 Chief Financial Officer